On one hand (left part, Figure 1), DCs are active players in orchestrating robust anti-tumor immunity by triggering cytotoxic CD8+ T-cells through TAA cross-presentation, recruiting and activating NK cells, ending up in tumor control. This evidence concerns the gene CD8A and neoplasm.